RheEnergise is an energy company that plans to transform pumped hydro technology and boost its capacity with its patented High-Density Hydro (HDH) technology. The company asserts that, by installing HDH on smaller hills and combining it with its HD Fluid R-19, businesses could produce 2.5 times the energy compared to low-density pumped-hydro. RheEnergise aims to install multiple HDH projects to meet the UK's growing energy needs. The company has agreements with entities like SSE, WelshPower, GreenCat Renewables and REG-Power. It is currently using its funding grants of ~£270,000 over the next nine months to build a defendable "Moat" of IP (Patents, Design and copyrights, know-how, and trade secrets) across six critical integrated sub-systems. The company will use the investment received to hire key personnel, progress patents, and accelerate its activities.
days to go:
Expired
investment:
£850,000
Active Needle Technology offers an award-winning "needle actuating device" which has high value medical and consumer applications. The company's patent-pending proprietary ultrasonic technology enhances visibility for medical needles in applications such as biopsy, in regional and joint anaesthesia and others. The company aims to commercialise its technology into a $4+ billion special purpose needle market. After identifying obvious commercial advantages in the tattoo market, Active Needle plans to use its ultrasonic needle technology to develop a low-pain tattooing system. Moreover, the company has won an Innovate UK grant to develop and test the tattoo device. With the proceeds, the company will complete CE marking for its initial biopsy device, for development of anaesthesia and tattooing products.
days to go:
Expired
investment:
£194,100
Innovate Recycle (IR) is a company that aims to reduce carbon emissions from burning discarded carpets. It asserts that only 2% of the 400,000 tonnes of discarded carpets in the UK is recycled, with the rest going into a landfill or being incinerated. IR further points out that burning waste carpet leads to an estimated CO2 impact of £16 million per annum in the UK. It wants to solve this crisis. IR is building a new carpet recycling plant in Northamptonshire that would be able to recycle carpets into reusable materials. They have already received grant funding of up to £2.35 million. IR claims that a single production line in the plant, at full capacity, can recycle up to 20,000 tonnes each year and generate 12,600 tonnes of polypropylene pellets. It will use the investment to expand to a second production line by Year 4 at the same facility.
days to go:
Expired
investment:
£2,650,000
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£326,190
Toraphene is an environmental technology company that aims to eliminate plastic waste. It has released with its product, Toraphene, to solve this crisis. It claims that Toraphene is a biodegradable, compostable and commercially-viable plastic packaging substitute for conventional plastic. The company asserts that its product is biodegradable even in the ocean, and has been developed using graphene technology. It is focussed on eliminating carrier bags and food containers in its first-round which account for 23% of marine waste. It aims to be a segment leader in the projected $25.4 billion biodegradable plastic industry by 2026. The company will use the investment to make Toraphene accessible to companies worldwide and make plastic packaging obsolete.
days to go:
Expired
investment:
£1,000,000
Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.
days to go:
Expired
investment:
£1,036,436
Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.
days to go:
Expired
investment:
£134,892
Square Mile Farms (SMF) is a company that installs innovative and productive vertical farms in a workplace to engage employees and help businesses create a culture of healthy, low-impact living. Its 'Office Farming' model creates green spaces for engagement and collaboration. In 2019, it was invited to build a vertical farm in Paddington Central by British Land, one of UK’s largest landowners. The setup now acts as a hub for the company's office farm installations and a base from which it can conduct Research and Development (R&D). SMF's customers include Grosvenor Group Limited and Vodafone. Moreover, the company has been covered by media platforms such as BBC One and BBC Radio. It will use 45% of the investment for sales and business development, 15% for design and technology up-gradation, 15% for raising its profile and increasing brand awareness, and 25% for operations.
days to go:
Expired
investment:
£504,118
Pharmseal is a software company that aims to disrupt clinical trial management. The company claims that companies typically use multiple applications for managing clinical trials from one or more vendors. This increases cost and complexity. Pharmaseal asserts that its cloud Business-2-Business (B2B) platform, Engility, simplifies control by providing a single management portal. The platform allows information to be centralised and accessed from a single platform. Pharmaseal claims that Engility will allow companies to save cost and time and enable them to bring life-saving drugs to market faster. The company will utilise 31% of the investment for commercialisation and marketing, 49% for product development, 13% for IT infrastructure, and 7% for administrative/legal/miscellaneous activities.
days to go:
Expired
investment:
£532,311
Jeeni is an online entertainment service that aims to harness the growing reach of streamed music. It has close to 350 million subscribers and a growth rate of 39% Year-on-Year (YoY) providing billion-dollar revenues for digital disruptors. The Jeeni prototype was launched in April 2019. The company asserts that it offers artists an ethical revenue share. Five revenue streams are operating in parallel on the Jeeeni platform, namely, subscription-based memberships, online masterclasses, bespoke hardware sales, pay-to-view streamed events, and branded merchandise sales. The company's long term goal is to surpass its target paid subscriber numbers, achieve high subscriber growth and exit by acquisition. The investment raised will be used to further scale the company's capacity globally and build its mass artist showcases.
days to go:
Expired
investment:
£118,854
